ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 660

Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis

María Galindo1, Elena Gonzalo-Gil2, Oscar Toldos3, Carmen García-Herrero2, Alicia Usategui1, Sonia Pérez-Yagüe4, Gabriel Criado5, Domingo F. Barber4 and Jose L. Pablos1, 1Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 2Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 3Servicio de Anatomia Patologica, Hospital 12 de Octubre, Madrid, Spain, 4Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, 5Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, Inflammation, lupus nephritis and platelets, Macrophage

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose

In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies. The aim of this study was to confirm these results in MRL/lpr mice and to analyze the specific effect of blocking inflammatory factors and/or platelet aggregation.

Methods

The pattern of renal vascular disease, acute and chronic glomerular and tubulointerstitial lesions were specifically analyzed with histological staining (H&E, PAS) in 12-20-wk old female MRL/lpr mice with nephritis. Immunohistochemistry (IHC) techniques were used to detect CD41 (platelet aggregates), fibrinogen (FGN), periglomerular macrophagic F4/80 (quantified as the % of positive glomeruli), intraglomerular macrophage infiltration (Mac-2) and C3 deposition. Renal function was assessed by measuring proteinuria, serum creatinine and albumin (sCr, sAlb). Levels of a-dsDNA and anticardiolipin (aCL) antibodies were quantified by ELISA. The specific effect of treatment with steroids and antiaggregation (aspirin or clopidogrel) was analyzed. Association between categorical variables was tested by the Χ2 test. For continuous variables, comparisons were carried out using t-test for two independent samples. A Spearman’s rank was used for correlations among different study parameters. P values < 0.05 were considered significant. 

Results

In the descriptive phase, 41 mice were analyzed. Histological, IHC and clinical characteristics of lpr mice with lupus nephritis are described in table 1.

Mice with microthrombotic renal vascular lesions showed a greater degree of periglomerular macrophage infiltration (p=0.002). All mice had detectable a-dsDNA or aCL IgG, irrespective of the presence of TMA or CD41+. Proteinuria positively correlated to the proportion of sclerotic glomeruli (r=0.4; p=0.01) and glomerular macrophage infiltration (r=0.46; p=0.004) and was higher in mice with diffuse proliferative glomerular lesions (340.8 vs110.8; p=0.02). 

After two weeks of treatment, the specific effect of 15 mg/d dexamethasone, 10 mg/d aspirin or 1.5 mg/d clopidogrel, or combined therapy dexa+ antiaggregation was compared to PBS treatment in 52 mice, and results are detailed in table 2.

Table 1

 

Mice (n=41)

Glomerular lesions:

   Focal and segmental proliferative

   Diffuse proliferative

Interstitial fibrosis

Instertitial inflammation:

   Medular

   Cortical

   Both

Mice with sclerotic glomeruli (number of glomeruli)

Microthrombotic renal vascular lesions (thrombotic microangiopathy [TMA] or CD41+ microthrombi)

Glomerular/extragomerular FGN (%)

Glomerular Mac-2 (%)

Periglomerular F4/80 (+ glom %)

Mean sCr (mg/dl)

Proteinuria (>300mg/dl)

–    

53.7%

46.3%

5%

–  

7.3%

29.3%

36.6%

46% (1-11)

34%

–   

4.8 ± 3.6/0.8 ± 0.6

3.9 ± 2.3

41.9 ± 21.4

0.5 ± 0.1

13.2%

Table 2

 

PBS

dexamethasone (15 ug/d)

aspirin /clopidogrel

(10 o 1,5 mg/d)

dexamethasone and antiaggregation

Exp1

N=8

N=9

↓ proteinuria **

↓a-dsDNA**

= aCL

= sCr and sAlb

↓CD41 (NS)

= C3 deposition

↓Mac-2*

↓F4/80**

N=8

↓ proteinuria **

↓a-dsDNA*

↓aCL*

= sCr and sAlb

↓CD41 (NS)

↓C3 deposition*

↓Mac-2*

↓F4/80**

N=8

↓ proteinuria*

↓ a-dsDNA**

↓ aCL*

= sCr and sAlb

↓ CD41 (NS)

= C3 deposition

↓Mac-2*

↓F4/80**

Exp2

N=4

N=4

↓proteinuria*

↓ a-dsDNA *

= aCL

= sCr and sAlb

↓CD41 (NS)

= C3 deposition

↓Mac-2*

↓F4/80*

N=6

↓proteinuria**

↓ a-dsDNA*

= aCL

= sCr and sAlb

↓CD41 (NS)

↓C3 deposition*

↓Mac-2**

↓F4/80**

N=5

↓ proteinuria**

↓ a-dsDNA (NS)

↓ aCL (NS)

= sCr and sAlb

↓CD41 (NS)

↓C3 deposition*

↓Mac-2*

↓F4/80*

Both

N=12

N=13

↓proteinuria***

↓ a-dsDNA*

= aCL

= sCr and sAlb

↓CD41 (NS)

= C3 deposition

↓Mac-2***

↓F4/80***

N=14

↓proteinuria***

= a-dsDNA

= aCL

= sCr and sAlb

↓CD41 (NS)

↓C3 deposition**

↓Mac-2***

↓F4/80***

N=13

↓ proteinuria**

↓ a-dsDNA*

↓ aCL**

= sCr and sAlb

↓CD41 (NS)

↓C3 deposition*

↓Mac-2**

↓F4/80***

*: p<0.05; **:p<0.01; ***: p<0.001; NS: no significant

Conclusion

Presence of microthrombotic renal vascular lesions is associated to a higher degree of macrophage infiltration in MRL/lpr model of LN. Both dexamethasone and blockers of platelet aggregation reduce glomerular damage and inflammatory response, suggesting platelets involvement in inflammatory damage.


Disclosure:

M. Galindo,
None;

E. Gonzalo-Gil,
None;

O. Toldos,
None;

C. García-Herrero,
None;

A. Usategui,
None;

S. Pérez-Yagüe,
None;

G. Criado,
None;

D. F. Barber,
None;

J. L. Pablos,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microthrombotic-renal-vascular-lesions-are-associated-to-increased-renal-inflammatory-infiltration-in-a-mouse-model-of-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology